Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies

 
• By John Davis

Lilly is targeting mRNA-based next-generation immunotherapies in its collaboration with Germany's CureVac, which could be worth more than $1.7bn for the family-office backed biotech.

Keys
Do immunotherapies hold the key to cancer? • Source: Shutterstock

More from Deals

More from Business